Daily non-political popular news in brief.

Drug treatment slows decline in lung function in COPD patients, TORCH study finds

Treatment with a commonly used drug slows the decline in lung function in patients with chronic obstructive pulmonary disease (COPD), according to results from the TORCH (TOwards a Revolution in COPD Health) study presented at the American Thoracic Society 2007 International Conference, on Tuesday, May 22.

Read more »

Keywords: drug, treatment, slows, decline, lung, function, copd, patients, torch, study, slow, patient

« Previous | Next »

Similar news on "Drug treatment slows decline in lung function in COPD patients, TORCH study finds":

1. A higher physical activity level slows lung function decline in smokers
   03-01-2007 · EurekAlert!
   Moderate to high levels of regular physical activity are associated with lower lung function decline among smokers and help to moderate their risk of developing chronic obstructive pulmonary disease (COPD), according to a large retrospective cohort study.
   Similar news · Read more »
   
2. High-dose ibuprofen may slow cystic fibrosis lung disease -- especially in children
   10-16-2007 · EurekAlert!
   This updated Cochrane Review supports the intriguing suggestion that long-term high-dose ibuprofen slows the rate of decline in lung function in children with cystic fibrosis when treatment is started under the age of 13.
   Similar news · Read more »
   
3. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
   05-21-2007 · EurekAlert!
   New product recently approved by FDA for long-term maintenance treatment of COPD bronchoconstriction; data demonstrate first nebulized formoterol fumarate provides improved lung function comparable to dry powder formoterol, enhanced patient quality of life, and positive safety profile.
   Similar news · Read more »
   
4. Chemo drugs for treating breast cancer may cause changes in cognitive function
   10-27-2006 · EurekAlert!
   A new study investigating the effects of chemotherapy on cognitive function in mice has confirmed what many cancer patients receiving treatment have often complained about -- a decline in their memory and other cognitive functions, sometimes characterized as "chemobrain."
   Similar news · Read more »
   
5. Transplant drug sirolimus shrinks tumors, improves lung function
   01-09-2008 · EurekAlert!
   The drug sirolimus, normally used to help transplant patients fight organ rejection, may eventually be used as a less invasive treatment for a tumor called angiomyolipomata in patients with tuberous sclerosis complex or lymphangioleiomyomatosis who would otherwise face surgery. The finding is reported by investigators from Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine in the Jan. 10 edition of the New England Journal of Medicine.
   Similar news · Read more »
   
6. 24-week course of interferon-alpha therapy prolongs survival in patients hepatitis C virus
   11-02-2007 · EurekAlert!
   A group at Hiroshima University Hospital performed a matched historical controlled study on whether a 24-week course of interferon-alpha therapy, after curative treatment for primary hepatocellular carcinoma associated with hepatitis C virus, could influence tumor recurrence, patient survival, and liver function. Patients with sustained virological responses had reduced recurrence, prolonged survival and a preserved liver function. The group also determined that viral eradication was the most important factor in such patients.
   Similar news · Read more »
   
7. Study shows cognitive decline is often undetected
   10-27-2006 · EurekAlert!
   Many patients over the age of 65 who are hospitalized with an acute illness experience a subtle change in their cognitive ability that often goes undiagnosed, untreated and under-reported. As a result, a patient's ability to make decisions about his or her medical treatment may be negatively impacted.
   Similar news · Read more »
   
8. Penn researchers find treatment for MS also reduces vision loss in MS patients
   04-16-2007 · EurekAlert!
   According to a study that appears in the April 17 issue of Neurology, researchers at the University of Pennsylvania School of Medicine have found that natalizumab (TYSABRI) -- a drug that slows disability and reduces relapse rates in patients with multiple sclerosis (MS) -- also reduces vision loss in patients with relapsing MS. Vision loss is one of the most common and disabling symptoms of MS.
   Similar news · Read more »
   
9. Cost control measures limit patient and physician choice in psychotropic medications
   03-01-2007 · EurekAlert!
   A new Brandeis University study published online in Clinical Therapeutics suggests that private health plans increasingly rely on escalating copayments to manage drug costs, as opposed to administrative controls. This makes treatment more expensive in many cases for patients, and may affect adherence to treatment, said lead author Dominic Hodgkin, associate professor at the Schneider Institute for Behavioral Health, Heller School for Social Policy and Management at Brandeis University.
   Similar news · Read more »
   
10. UCLA researchers discover biomarkers that predict lung cancer patient response to therapy
    01-31-2008 · EurekAlert!
    Researchers at UCLA's Jonsson Cancer Center have discovered biomarkers that predict which patients with advanced non-small cell lung cancer will respond to a combination treatment of the anti-inflammatory drug Celebrex and the growth factor receptor blocker Tarceva.
    Similar news · Read more »